Fabino Enterprises last traded at ₹20.31 (2026-10-13). Over the past month the stock moved +0.0%, three months the stock moved +0.0%, year the stock moved -11.7%. Its closing range over 52 weeks is ₹13.10 – ₹27.00, with the latest close 24.8% below the high.
Closing prices up to 2026-10-13.
Incorporated in 2011, Fabino Enterprises manufactures, markets, trades, and does packing of pharmaceutical and other wellness focused consumer products[1]
Business Overview:[1][2] a) FEL is an ISO 9001:2015 pharmaceutical company located near the Delhi NCR region. It offers a wide range of allopathic and herbal products. b) Company markets pharmaceutical formulation for domestic market and sells through own distribution network and sales force under their own brand name c) It gets Ayurvedic formulations manufactured through Loan Licensing facilities, Packing, Labelling etc. d) Company exports wellness and FMCG products like Coffee, Malt powder, Protein powder, Hair shampoo which it also markets
In the latest quarter (Mar 2026), Fabino Enterprises reported sales of ₹14.21 crore (+72.9%) and net profit of ₹-0.37 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 14.21 | -1.75 | -12.32 | -0.37 | -1.76 |
| Sep 2025 | 6.63 | -0.32 | -4.83 | -0.19 | -0.90 |
| Mar 2025 | 13.78 | 0.08 | 0.58 | 0.03 | 0.14 |
| Sep 2024 | 4.25 | 0.03 | 0.71 | 0.03 | 0.14 |
| Mar 2024 | 8.22 | -0.01 | -0.12 | -0.05 | -0.24 |
| Sep 2023 | 12.86 | 0.12 | 0.93 | 0.09 | 0.43 |
| Mar 2023 | 2.32 | 0.02 | 0.86 | 0.00 | 0.00 |
| Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|
| Sales growth | +494.0% | -48.4% | +72.9% |
| Operating profit growth | +300.0% | -366.7% | – |
| Net profit growth | – | -311.1% | – |
| EPS growth | – | -309.3% | – |
| OPM % | 0.6% | -4.8% | -12.3% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Fabino Enterprises reported sales of ₹20.84 crore (+15.5%) and net profit of ₹-0.56 crore (-1033.3%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 20.84 | -2.06 | -9.88 | -0.56 | -2.67 |
| Mar 2025 | 18.04 | 0.11 | 0.61 | 0.06 | 0.29 |
| Mar 2024 | 21.01 | -0.18 | -0.86 | 0.04 | 0.19 |
| Mar 2023 | 3.36 | 0.03 | 0.89 | 0.01 | 0.05 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales growth | +525.3% | -14.1% | +15.5% |
| Operating profit growth | -700.0% | – | -1972.7% |
| Net profit growth | +300.0% | +50.0% | -1033.3% |
| EPS growth | +280.0% | +52.6% | -1020.7% |
| OPM % | -0.9% | 0.6% | -9.9% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Fabino Enterprises.
Get Free AI Stock Analysis FREE →Fabino Enterprises open offer to acquire 26% at ₹20 per share - scanx.trade
Fabino Enterprises shares were last quoted at ₹20.31 (+0.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Fabino Enterprises has a price-to-earnings (P/E) ratio of -11.88 and a price-to-book (P/B) ratio of 1.17. The industry P/E is 53.45.
The 52-week high of Fabino Enterprises is ₹38.96 and the 52-week low is ₹13.01.
The market capitalisation of Fabino Enterprises is about ₹4.27 crore.
In the latest quarter (Mar 2026), Fabino Enterprises reported sales of ₹14.21 crore (+72.9%) and net profit of ₹-0.37 crore, compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Fabino Enterprises has a 3-year ROE of -4.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 56.82% of Fabino Enterprises.
Fabino Enterprises belongs to the Pharmaceuticals & Drugs sector.